Pediatr Gastroenterol Hepatol Nutr.
2012 Mar;15(1):19-22.
Recent Trends of Infliximab Treatment for Crohn's Disease
- Affiliations
-
- 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. i101016@skku.edu
Abstract
- Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract and characterized by relapsing and remitting episodes, with progression over time to complications of stricture, fistulas, or abscesses. The etiology is unknown, although the common opinion is that the disease arises from a disordered immune response to the gut contents in genetically predisposed individuals. Infliximab is a mouse-human chimeric antibody against tumor necrosis factor alpha, and has proven to be effective in active Crohn's disease for both induction and maintenance therapy. Despite the growing experience with infliximab in Crohn's disease, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of infliximab in Crohn's disease and to discuss the yet-unsolved issues.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease
- Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
- A Case of Infliximab-induced Psoriasis in Treatment of Ankylosing Spondylitis
- A Pityrosporum Fungal Infection Following Infliximab Therapy in a Crohn's Disease Patient
- Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
